• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
HRTX

HRTX

Heron Therapeutics, Inc.

NASDAQHealthcareBiotechnologyUS

USD0.45

-0.00 (-0.71%)

Rating:C

Company Profile

CEO

Craig Alexander Collard

IPO Date

1987-08-26

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.48

Prev. Close

$0.45

Day Low

$0.43

Day High

$0.52

52W Low

$0.43

52W High

$2.30

Market Cap

$0.07B

Volume

10.79M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

58.6%

Avg Negative

1.3%

Avg Neutral

39.7%

News Feed

Heron Therapeutics Announces Publication of Results from HOPE (Helping Opioid Prescription Elimination), Showing ZYNRELEF™ Minimizes the Need for Opioids in a Real-World Setting, With 95% of Patients Experiencing an Opioid-free Recovery

PRNewsWire·7/28/2021·↑ positive

Heron Therapeutics' Zynrelef Shows Reduction In Post-Op Pain, Opioid Use Compared To Bupivacaine In Old-Aged Patients

Benzinga·7/22/2021·↑ positive

Heron Therapeutics Announces Publication Showing Reduction of Pain and Opioid Use Compared to Bupivacaine in Patients 65 and Older with ZYNRELEF™

PRNewsWire·7/21/2021·↑ positive

Heron Therapeutics Announces 340B Prime Vendor Contract with Apexus for ZYNRELEF™

PRNewsWire·7/6/2021·↑ positive

Heron Therapeutics Announces U.S. Commercial Launch and Availability of ZYNRELEF™ for the Management of Postoperative Pain for up to 72 Hours

PRNewsWire·7/1/2021·↑ positive

Under Biden's Budget, These 2 Little-Known Biotechs Could Help End the Opioid Crisis

The Motley Fool·6/2/2021·↑ positive

Heron Therapeutics to Present at the 2021 Jefferies Virtual Investor Conference

PRNewsWire·5/25/2021·↑ positive

Heron Therapeutics: Zynrelef (Finally) Approved But With A Narrow Label

Seeking Alpha·5/21/2021·↑ positive

Heron's Non-Opioid, Post-Operative Pain Drug Approved By FDA: Why This Is Important

Benzinga·5/13/2021·↑ positive

Heron Therapeutics (HRTX): Over 15% Increase Pre-Market Explanation

Pulse2·5/13/2021·↑ positive